Effects and Mechanisms of Temporal Interference Stimulation (TIS) on Neuropathic Pain (TIS)
29 juli 2026 uppdaterad av: Second Affiliated Hospital, School of Medicine, Zhejiang University
This study employs temporal interference stimulation (tTIS) to investigate the analgesic effects of tTIS on neuropathic pain and monitor changes in neural plasticity, and explore the dynamic relationship between analgesic efficacy and neural plasticity, thereby providing new strategies for the treatment of neuropathic pain.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
60
Fas
- Inte tillämpbar
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- IASP diagnosis of peripheral neuropathic pain;
- At least one month after the onset of pain;
- At least moderate pain intensity (≥ 3 assessed by VAS or NRS);
- 18 years or older;
- Stable medical treatment from 2 weeks before allocation to the end of the trial;
- Willing to receive TIS treatment and capable of fulfilling clinical assessments.
Exclusion Criteria:
- Contradictions to TIS treatment, such as metal implants or seizure;
- Serious psychiatric disorder (Hamilton Depression Rating Scale score ≥ 35 or Hamilton Anxiety Rating Scale score ≥ 29);
- Aphasia or cognitive disorders (Mini mental state examination ≤ 24);
- Severe clinical disorders caused by tumor or other conditions;
- Severe cardiopulmonary dysfunction or extreme weakness;
- History of substance abuse (alcohol, drugs).
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: tTIS group
Following enrollment, patients underwent TIS treatment administered twice daily over five consecutive days, for a total of ten sessions.
The stimulation was targeted at the periaqueductal gray (PAG) region contralateral to the side of pain.
Assessments were conducted before treatment (T0) and immediately after the treatment course (T1), evaluating pain perception, emotional changes, and quality of life.
Additionally, local and whole-brain mechanisms were examined using TIS-EEG and fMRI.
|
tTIS was applied to the PAG contralateral to the pain side for a duration of 20 minutes, comprising a 30-second ramp-up phase and a 30-second ramp-down phase.
Andra namn:
|
|
Sham Comparator: Sham group
The sham group followed the same procedure as the TIS group.
However, the electrical current was only delivered in a 30-second ramp-up at the beginning and a 30-second ramp-down at the end of each session to replicate the initial peripheral sensation without providing sustained therapeutic stimulation.
|
tTIS was applied to the PAG contralateral to the pain side for a duration of 20 minutes, comprising a 30-second ramp-up phase and a 30-second ramp-down phase.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
visual analogue scale(VAS)
Tidsram: Day1(Baseline), day 5 after intervention
|
It typically consists of a 10-centimeter straight line, with two endpoints representing extreme states of the measured experience.
For example, when assessing pain, one end is labeled "0 (no pain at all)" and the other end "10 (worst pain imaginable, unbearable)".
|
Day1(Baseline), day 5 after intervention
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
short-form McGill Pain Questionnaire (SF-MPQ)
Tidsram: Day1(Baseline), day 5 after intervention
|
The Pain Rating Index of the Short-Form McGill Pain Questionnaire consists of 15 pain descriptors, including 11 sensory descriptors and 4 affective descriptors.
Each item is rated from 0 (none) to 3 (severe).
Item scores are summed to produce a total score ranging from 0 to 45, with higher scores indicating greater pain severity.
The outcome measure is the change in the total Pain Rating Index score from baseline to Day 5 after intervention.
|
Day1(Baseline), day 5 after intervention
|
|
Brief Pain Inventory (BPI)
Tidsram: Day1(Baseline), day 5 after intervention
|
0 = "does not interfere" to 10 = "interferes completely" based on the past 24 hours.
|
Day1(Baseline), day 5 after intervention
|
|
The Patient Global Impression of Change (PGIC)
Tidsram: Day1(Baseline), day 5 after intervention
|
Single-item structure: It consists of a single question that asks patients to rate how much their condition has changed since a specified baseline.2.7-point response scale: Responses range from "very much improved" (score 1) to "very much worse" (score 7), with intermediate options including "much improved," "minimally improved," "no change," "minimally worse," and "much worse."
|
Day1(Baseline), day 5 after intervention
|
|
17-items of Hamilton Depression Rating Scale (HAMD)
Tidsram: Day1(Baseline), day 5 after intervention
|
The HAMD-17 provides a comprehensive, multi-dimensional snapshot of depression severity, heavily emphasizing sleep, physical (somatic), and anxiety symptoms alongside core mood symptoms
|
Day1(Baseline), day 5 after intervention
|
|
The Beck Depression Inventory-II (BDI-II)
Tidsram: Day1(Baseline), day 5 after intervention
|
BDI-II is a widely used self-report questionnaire designed to assess the severity of depressive symptoms in adults and adolescents.It consists of 21 items, each describing a specific depressive symptom (e.g., sadness, loss of interest, guilt, fatigue, sleep disturbances, appetite changes).
|
Day1(Baseline), day 5 after intervention
|
|
TIS-EEG: Mean Change From Baseline in Resting-State Posterior Alpha-Band Relative Power at Day 5
Tidsram: Day 1 before the first intervention and Day 5 within 30 minutes after completion of the final intervention
|
A 5-minute eyes-closed resting-state electroencephalography recording will be obtained before the first intervention and after the final intervention.
|
Day 1 before the first intervention and Day 5 within 30 minutes after completion of the final intervention
|
|
Mean Within-Session Change in Alpha-Band Relative Power During Transcranial Temporal Interference Stimulation on Day 5
Tidsram: During the 20-minute transcranial temporal interference stimulation session on Day 5
|
Electroencephalography will be continuously recorded during the 20-minute transcranial temporal interference stimulation session.
After removal of stimulation-related and physiological artifacts using a prespecified preprocessing procedure, alpha-band relative power will be calculated within the 8-13 Hz frequency range and averaged across all included electroencephalography electrodes.
Relative alpha power will be calculated as alpha-band power divided by total power within the 1-45 Hz frequency range and multiplied by 100.
The within-session change will be calculated as the mean relative alpha power during the final 5 minutes of stimulation minus the mean relative alpha power during the first 5 minutes of stimulation and reported in percentage points.
|
During the 20-minute transcranial temporal interference stimulation session on Day 5
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 augusti 2026
Primärt slutförande (Beräknad)
31 december 2027
Avslutad studie (Beräknad)
31 januari 2028
Studieregistreringsdatum
Först inskickad
9 februari 2026
Först inskickad som uppfyllde QC-kriterierna
29 juli 2026
Första postat (Faktisk)
30 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
30 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
29 juli 2026
Senast verifierad
1 januari 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2025-1132
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .